Hemab Therapeutics Holdings Inc (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing product candidates for blood coagulation disorders. The company generates no product revenue, funding operations through equity financing across multiple rounds of convertible preference shares and convertible preferred stock, as disclosed in its 10-Q filed 2026-05-21. As of March 31, 2026, the company holds cash, cash equivalents, and marketable securities as its primary assets, and carries an accumulated deficit reflecting its pre-commercial status. Hemab has no approved products, no sales or marketing infrastructure, and no commercial distribution capability. The company intends to target the United States and Europe as its commercial markets, pending regulatory approvals that have not yet been obtained. The capital structure reflects a stockholders' deficit as of March 31, 2026, with operations dependent on additional fundraising. Intellectual property protection is a stated priority, with patent prosecution and maintenance costs factored into operating expenses.

Revenue model

No product revenue as of the 10-Q filed 2026-05-21. Operations are financed through equity issuances, including multiple series of convertible preference shares and convertible preferred stock. The company has not established a commercial pricing structure or obtained payor reimbursement approvals.

Products and services

The filing references product candidates in development for blood coagulation disorders but does not name specific compounds or disclose pipeline stage details in the excerpts provided.

Customers and end markets

No commercial customers as of the 10-Q filed 2026-05-21. Target end markets, pending regulatory approval, are the United States and Europe. End market is blood coagulation disorders, with anticipated reliance on third-party and government payor reimbursement.

Value-chain role

Pre-commercial drug developer. The company conducts preclinical studies and clinical trials but has no manufacturing, sales, marketing, or distribution infrastructure as of the filing date.

Geographic exposure

Operations include activities in Denmark, reflected by DKK-denominated par values for convertible preference shares. Planned commercial markets include the United States and Europe, per the 10-Q filed 2026-05-21.

Source: SEC 10-Q, filed 2026-05-21

Industry: Biological Products, (No Diagnostic Substances)